Anaplastic Large Cell Lymphoma Therapeutics Global Market Report 2025

The anaplastic large cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $10.98 billion in 2024 to $11.72 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing awareness about cancer, the rising incidence of anaplastic large cell lymphoma, advancements in medical research, growing awareness of early diagnosis, and improved adoption of existing treatment options.

The anaplastic large cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $14.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to a greater focus on immuno-oncology, regulatory support for new treatments, government initiatives and funding, rising investments in research and development, and increasing patient advocacy efforts. Major trends include advancements in targeted therapies, the development of novel drug conjugates, a growing emphasis on personalized medicine, increased adoption of combination therapies, and technological advancements in diagnostics.

The increasing adoption of targeted therapies is expected to drive the expansion of the anaplastic large cell lymphoma therapeutics market. Targeted therapies are advanced treatments designed to specifically inhibit molecules or pathways responsible for cancer progression, minimizing harm to healthy cells. The demand for these therapies is rising due to factors such as advancements in precision medicine, growing clinical research and innovations, and the increasing incidence of cancers. In the case of anaplastic large cell lymphoma (ALCL), targeted therapies selectively attack cancer cells with specific molecular alterations, such as ALK gene rearrangements or CD30 expression. This approach enhances treatment efficacy, reduces damage to healthy tissues, lowers systemic toxicity, and improves patient outcomes through precision medicine. For example, in July 2023, a report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drug and device intelligence, indicated that the number of gene therapies in Phase II clinical trials increased from 247 at the end of Q1 2023 to 260 by the end of Q2, reflecting a 5% rise. Consequently, the rising adoption of targeted therapies is contributing to the growth of the anaplastic large cell lymphoma therapeutics market.

Leading companies in the anaplastic large cell lymphoma therapeutics market are prioritizing investments in clinical trials to enhance treatment effectiveness and broaden therapeutic options. Funding clinical trials involves allocating financial and resource commitments to develop, test, and evaluate new drugs, therapies, or medical devices, ensuring their safety, efficacy, and regulatory approval. For instance, in November 2023, March Biosciences, a US-based clinical-stage cell therapy company, secured a $4.8 million investment from the Cancer Focus Fund to support its Phase 2 clinical trial of MB-105, a novel CAR-T therapy targeting CD5 for the treatment of relapsed T-cell leukemias and lymphomas. The open-label, multi-center trial will evaluate MB-105 in patients with CD5-positive relapsed or refractory T-cell lymphoma. March Biosciences anticipates that MB-105 could become a first-in-class, life-saving therapy for relapsed T-cell lymphoma patients who have limited treatment options.

In June 2024, Takeda Pharmaceutical Company, a Japan-based pharmaceutical firm, entered into a partnership with Pfizer Inc. to improve treatment outcomes for lymphoma patients by evaluating ADCETRIS (brentuximab vedotin). Under this collaboration, Pfizer will hold commercialization rights for ADCETRIS in the U.S. and Canada, while Takeda will retain commercialization rights in the rest of the world and manage regulatory filings outside of the U.S. and Canada. Pfizer Inc. is a US-based developer of ADCETRIS (brentuximab vedotin) for the treatment of anaplastic large cell lymphoma.

Major players in the anaplastic large cell lymphoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Fresenius Kabi, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Genmab A/S, Seagen Inc., Spectrum Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Kite Pharma, MEI Pharma Inc., Cell Signaling Technology Inc., Acrotech Biopharma Inc., Xenothera, Citius Pharmaceuticals Inc., Seattle Genetics Inc.

North America was the largest region in the anaplastic large cell lymphoma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic large cell lymphoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anaplastic large cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anaplastic large cell lymphoma (ALCL) therapeutics encompass various treatment strategies designed to manage this rare and aggressive T-cell non-Hodgkin lymphoma (NHL). The primary objective is to eliminate malignant T-cells, achieve remission, and minimize the risk of relapse while reducing adverse effects.

The main disease types for ALCL therapeutics include primary anaplastic large cell lymphoma and relapsed anaplastic large cell lymphoma. Primary ALCL is an aggressive form of non-Hodgkin lymphoma characterized by abnormal T-cell proliferation, often affecting lymph nodes or the skin, and is typically treated with chemotherapy regimens such as CHOP for improved outcomes. Treatment options include chemotherapy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), as well as targeted therapies such as brentuximab vedotin and pralatrexate, along with surgery, radiation therapy, and stem cell transplantation. These therapies are used across various applications, including inpatient and outpatient settings.

The anaplastic large cell lymphoma therapeutics market research report is one of a series of new reports that provides anaplastic large cell lymphoma therapeutics market statistics, including the anaplastic large cell lymphoma therapeutics industry global market size, regional shares, competitors with the anaplastic large cell lymphoma therapeutics market share, detailed anaplastic large cell lymphoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the anaplastic large cell lymphoma therapeutics industry. This anaplastic large cell lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anaplastic large cell lymphoma therapeutics market consists of revenues earned by entities by providing services such as immunotherapy, supportive care and symptom management, personalized treatment planning, post-treatment monitoring, and relapse prevention. The anaplastic large cell lymphoma therapeutics market also includes sales of antibody-drug conjugates and chemotherapy agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.